Biotech startup Kallyope snags $44 mln Series A
New York City-based Kallyope Inc, a biotech company focused on "harnessing the potential of the gut-brain axis," has launched with $44 million in Series A funding. The company's investors include Lux Capital, Polaris Partners, The Column Group, Illumina Inc and Alexandria Venture Investments.
10 December 2015•4 mins read
